Skip to main content

Table 1 Patient characteristic of the overall cohort (n = 128) and after stratification for presence of MVO

From: Multimarker approach for the prediction of microvascular obstruction after acute ST-segment elevation myocardial infarction: a prospective, observational study

Patient characteristics Overall cohort Presence of MVO
(n = 128) no (n = 59, 46%) yes (n = 69, 54%) p
Age, years 58 ± 10 57 ± 10 58 ± 10 0.925
Female, n (%) 12 (9) 8 (14) 4 (6) 0.223
Body mass index, kg/m2 26 (25–30) 27 (26–29) 26 (24–30) 0.522
Family history for AMI, n (%) 34 (27) 19 (32) 15 (22) 0.229
Current smokers, n (%) 63 (49) 28 (48) 35 (51) 0.727
RRsys, mmHg 125 ± 24 126 ± 23 123 ± 24 0.491
RRdia, mmHg 77 ± 15 78 ± 14 76 ± 15 0.309
Leucocyte count admission, G/l 11.7 (8.8–14.5) 11.5 (8.5–14.5) 12.0 (9.0–14.6) 0.649
Leucocyte count max, G/l 12.7 (10.8–15.8) 11.9 (10.3–15.2) 13.1 (11.7–16.4) 0.061
Total cholesterol, mg/dl 192 ± 44 185 ± 41 198 ± 47 0.108
Low-density lipoprotein, mg/dl 128 ± 42 123 ± 39 132 ± 44 0.230
High-density lipoprotein, mg/dl 42 (36–49) 40 (33–53) 43 (38–49) 0.320
Triglycerides, mg/dl 102 (78–151) 108 (80–163) 96 (77–142) 0.276
Plasma glucose admission, mg/dl 135 (115–161) 134 (116–163) 137 (112–160) 0.728
HbA1c, % 5.6 (5.4–6.0) 5.6 (5.4–6.1) 5.6 (5.3–5.9) 0.792
Creatinine admission, mg/dl 0.93 (0.82–1.05) 0.92 (0.76–1.07) 0.93 (0.83–1.04) 0.877
Creatinine max, mg/dl 1.04 (0.92–1.15) 1.03 (0.91–1.13) 1.06 (0.96–1.20) 0.261
hs-cTnT admission, ng/l 226 (29–2168) 201 (18–1388) 523 (34–4001) 0.036
hs-cTnT max, ng/l 5254 (2169–8735) 2866 (1026–5524) 6985 (4193–13639) <0.001
CK admission, U/l 353 (174–1182) 301 (148–862) 435 (207–2433) 0.048
CK max, U/l 2111 (1168–3674) 1228 (625–2323) 2776 (1749–4686) <0.001
NT-proBNP admission, ng/l 139 (66–511) 128 (66–360) 159 (71–687) 0.487
NT-proBNP max, ng/l 717 (184–1700) 360 (131–924) 1084 (312–2649) 0.003
hs-CRP admission, mg/dl 0.23 (0.11–0.61) 0.34 (0.15–0.66) 0.19 (0.09–0.56) 0.119
hs-CRP max, mg/dl 2.20 (0.96–4.56) 1.53 (0.64 3.02) 2.84 (1.68–7.44) <0.001
LDH admission, U/l 238 (196–364) 222 (182–301) 257 (207–493) 0.009
LDH max, U/l 593 (354–882) 358 (271–624) 742 (534–1182) <0.001
AST admission, U/l 82 (34–210) 57 (31–113) 126 (40–306) 0.008
AST max, U/l 239 (128–423) 151 (75–256) 340 (213–547) <0.001
ALT admission, U/l 37 (27–58) 31 (25–46) 45 (32–75) 0.003
ALT max, U/l 60 (42–87) 47 (32–69) 71 (52–111) <0.001
γGT admission, U/l 37 (25–52) 36 (26–50) 39 (23–59) 0.857
γGT max, U/l 40 (26–63) 37 (26–51) 41 (26–71) 0.482
AP admission, U/l 64 (53–79) 64 (52–80) 63 (54–76) 0.918
AP max, U/l 64 (53–81) 64 (52–83) 64 (54–81) 0.951
Total bilirubin admission, mg/dl 0.49 (0.38–0.69) 0.44 (0.37–0.65) 0.52 (0.40–0.73) 0.160
Total bilirubin max, mg/dl 0.62 (0.43–0.84) 0.60 (0.42–0.84) 0.62 (0.45–0.85) 0.668
  1. MVO Microvascular Obstruction, AMI Acute Myocardial Infarction, RR sys Systolic Blood Pressure, RR dia Diastolic Blood Pressure, hs-cTnT High-Sensitivity Cardiac Troponin T, CK Creatine Kinase, NT-proBNP N-terminal pro-B-type natriuretic peptide, hs-CRP High-Sensitivity C-Reactive Protein, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT Alanine Transaminase, γGT Gamma-Glutamyltransferase, AP Alkaline Phosphatase
  2. Bold data indicate statistical significance